About this trial
Prostate cancer is the most common type of cancer in Norwegian men, but many tumors are slow-growing and do not require treatment. Today, MRI is good at detecting suspicious lesions, yet it cannot reliably distinguish aggressive tumors from low-grade ones. As a result, many men undergo repeated invasive biopsies. New PET tracers targeting PSMA improve tumor localization and may correlate with cancer aggressiveness, offering potential for better assessment.
This project aims to develop a method to predict Gleason Score non-invasively by applying machine learning to PET and MRI data. The work involves early static and dynamic PSMA PET imaging, tracer kinetic modelling, deep learning, and validation of PET-based measurements of PSMA internalization using ex-vivo cellular methods.
If successful, the project could reduce the number of biopsies, improve diagnostic accuracy, offer full 3D assessment of the prostate, shorten clinical workflows, and help identify patients who would benefit most from PSMA-based radioligand therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients referred to clinical PET examination
Patients referred to urologist for suspected prostate cancer based on clinical symptoms or elevated PSA-levels
Disqualifiers
Prostatektomy
Body weight under 100 kg
MRI incompatible implants or other incompatibilities
Trial population
Primary prostate cancer patients.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
PET imaging
Dynamic and static PET imaging of participants including blood samples
Sponsors and contacts
Click on the lead sponsor to view all of their trials.